Lapatinib
Lapatinib
Lapatinib (pronounced la-pa-ti-nib) is a tyrosine kinase inhibitor and a type of targeted therapy used in the treatment of certain types of breast cancer and other cancers. It is also known by its brand name, Tykerb.
Etymology
The name "Lapatinib" is derived from the scientific name of the compound, which is N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine. The "Lap" in Lapatinib is likely a reference to the compound's inhibitory action on the Lapatinib protein.
Usage
Lapatinib is used in combination with other chemotherapy drugs to treat HER2-positive breast cancer that has progressed after treatment with other, more standard therapies. It works by blocking the signals in the cancer cells that make them grow and divide.
Related Terms
- Tyrosine kinase inhibitor: A type of drug that blocks the action of enzymes known as tyrosine kinases, which can stimulate the growth of cancer cells.
- Targeted therapy: A type of cancer treatment that uses drugs to target specific genes and proteins that are involved in the growth and survival of cancer cells.
- Breast cancer: A type of cancer that forms in the cells of the breasts.
- HER2-positive: A term used to describe a type of breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2), which promotes the growth of cancer cells.
External links
- Medical encyclopedia article on Lapatinib
- Wikipedia's article - Lapatinib
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski